# Novartis Ends Phase 2 Fabhalta Trial for Lupus Kidney Disease

By John Kim

Canonical URL: https://www.tokenpost.com/news/business/33774
Published: 2026-10-17T05:44:31.000Z
Updated: 2026-10-17T05:44:31.000Z
Section: Business

> In an Oct. 15 update, Novartis gave strategic considerations as the reason after Part 1’s final patient completed the last visit.

Novartis ended its Phase 2 trial of Fabhalta (iptacopan) for lupus nephritis for strategic reasons after the final patient completed the last visit in Part 1.

Fabhalta is an oral Factor B inhibitor. The study tested it alongside standard-of-care treatment for lupus nephritis, an inflammatory kidney condition associated with lupus.